EXCLUSIVE LIFE SCIENCE FEATURE
leaders
LIFESCIENCELEADER.COM JULY 2014
26
J&J;'S APPROACH TO CAPTURING
J&J;'S
APPROACH
TO
CAPTURING
DISRUPTIVE
INNOVATION
IN
CLINICAL
TRIALS
By
W.
Koberstein
In the pharmaceutical industry, gaps often exist between companies and
internal working groups. Consider one of the industry's largest players,
Johnson & Johnson (NYSE: JNJ), which has more than 127,000 employees
and operates more than 250 companies organized into several business
segments in 60 countries.
&J;'s pharmaceutical segment
consists of six Janssen pharma-
ceutical companies, including
Janssen R&D;, which contains the Janssen
Healthcare Innovation ( JHI) team. And
while the R&D; arm is focused on dis-
covering and developing medicines for
unmet medical needs, JHI's vision is to
help accelerate the transformation of
J&J; from a healthcare product company
to simply a healthcare company.
To bridge the gap between the two, as
well as facilitate external collaborative
alliances with consumers and companies,
J&J; created Clinical Trial Innovation (CTI)
Ñ an organization integrated with JHI
and Janssen R&D; Operations. Headed by
20+ year R&D; veteran Andreas Koester,
M.D., Ph.D., CTI has some ambitious goals
Ñ develop solutions that will modern-
ize clinical trials, improve data quality,
and enhance the clinical trial process for
patients and investigators. Having 13 new
medicines approved in the last decade, J&J;
ranks at the pinnacle of the most produc-
tive pharmas, and perhaps is one of the
most disruptively innovative. Koester, VP
of clinical trial innovation and external
alliances, shares what the CTI team is
doing to keep it that way.
J
IN CLINICAL TRIALS
W A Y N E K O B E R S T E I N Executive Editor
0 7 1 4 _ F e a t u r e _ J a n s s e n 3 . i n d d 1 0714_Feature_Janssen3.indd 1 6 / 2 0 / 2 0 1 4 1 1 : 5 6 : 3 3 A M 6/20/2014 11:56:33 AM